QIAGEN (QGEN) Gets Exclusive Rights to Biomarkers
Tweet Send to a FriendGet Alerts QGEN Hot Sheet
Down)
Trade QGEN Now!
QIAGEN (Nasdaq: QGEN) has announced two agreements with U.S. biotech companies to acquire worldwide exclusive rights to biomarkers that are expected to play an important role in personalized treatment of various cancers.
QIAGEN has entered into a strategic co-development partnership and licensing agreement with Insight Genetics, Inc. of Nashville, Tennessee, for a genetic test covering the ALK (anaplastic lymphoma kinase) biomarker, a promising target for a novel class of lung cancer drugs.
Through a separate agreement between its 89% subsidiary Ipsogen and Personal Genome Diagnostics Inc., of Baltimore, Maryland, QIAGEN has also acquired worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes - which are believed to play a role in brain cancers, acute myelogenous leukemia (AML) and certain other malignancies.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
QIAGEN has entered into a strategic co-development partnership and licensing agreement with Insight Genetics, Inc. of Nashville, Tennessee, for a genetic test covering the ALK (anaplastic lymphoma kinase) biomarker, a promising target for a novel class of lung cancer drugs.
Through a separate agreement between its 89% subsidiary Ipsogen and Personal Genome Diagnostics Inc., of Baltimore, Maryland, QIAGEN has also acquired worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes - which are believed to play a role in brain cancers, acute myelogenous leukemia (AML) and certain other malignancies.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Sprint (S) to Raise Offer for Clearwire (CLWR) - DJ
- Philip Morris (PM) Will Acquire Balance of Mexico Unit in $700M Deal
- Abbott (ABT) Receives CE Mark for XIENCE Coronary Stent System
Create E-mail Alert Related Categories
Corporate News, FDA, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
